Scholars Central

Conference abstractPublished 8 Sep 2014

Are life sciences companies frightened of “the cloud”?

Authors: David Hawley

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

While industry in general and society as a whole increases its use of Cloud Services, and gains the benefit of the flexibility, rapid response and lowered cost that characterizes these systems, there is one area of industry that stands fearfully on the sidelines - Life Sciences. For a sector that touts its cutting-edge technology and blue-sky vision, the situation is different when it comes to the use of new technologies from other industries, Pharmaceutical, Medical device and similar companies are barely using cloud systems for any services that fall under the scope of the Code of Federal Regulations (or similar rules world-wide). Those that are using such systems mostly confine it to a few well-established vendors of Sales systems, and the like. Is the Life Sciences Industry right to be wary? Do the regulatory authorities deprecate cloud systems and how do you actually define a cloud-based system in any case? This talk will outline the situation as it exists now, critically examine some common myths, and suggest some ways forward.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “David Hawley”